Organisation: Behrman Capital

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

Elan, Biogen shares rise on drug trials

ELAN and Biogen share prices rose immediately yesterday on the back of positive results in trials of their Antegren drug in patients with multiple sclerosis and Crohn's disease.

Fri, 03 Jan, 2003

Elan shares rise on positive finding on Antegen

Shares in Elan rose over 12% in trading on Nasdaq on Tuesday December 31, as a result of a positive report on Antegen and on news of its realising further cash.

Thu, 02 Jan, 2003

Elan to realise $122m on Athena sale

Elan and stockholders of its subsidiary, Athena Diagnostics, have agreed to sell all outstanding stock of Athena Diagnostics to Behrman Capital for $122m (€122.6m).

Mon, 25 Nov, 2002